Screener
Corvus Pharmaceuticals CRVS Total Current Assets
Total Current Assets at other companies
Other financials
Where this comes from
Reported directly by Corvus Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:AssetsCurrent.
The source filing: Corvus Pharmaceuticals’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:05 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001104659-26-057100
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| Marketable securities | 196,612 | 52,174 |
| Accounts receivable - related party | 43 | 37 |
| Prepaid and other current assets | 3,189 | 1,427 |
| Total current assets | 239,946 | 58,214 |
| Property and equipment, net | 282 | 220 |
| Operating lease right-of-use asset | 751 | 839 |
| Investment in Angel Pharmaceuticals | 10,496 | 10,991 |
| Other assets | 1,720 | 855 |
Item 1. Financial Statements (unaudited)
FAQ
- What is Corvus Pharmaceuticals's total current assets?
- Corvus Pharmaceuticals (CRVS) reported total current assets of $239.95M in Q1 2026.
- How has Corvus Pharmaceuticals's total current assets changed year-over-year?
- Corvus Pharmaceuticals's total current assets increased by 427.5% year-over-year, from $45.49M to $239.95M.
- What is the long-term trend for Corvus Pharmaceuticals's total current assets?
- Over 5 years (2020 to 2025), Corvus Pharmaceuticals's total current assets has grown at a 5.1% compound annual growth rate (CAGR), from $45.34M to $58.21M.
- What does total current assets mean?
- The sum of all assets expected to be converted to cash or consumed within one year — cash, receivables, inventory, and prepaid expenses.
Ask your AI about Corvus Pharmaceuticals's total current assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude